Lipid-modifying agents, from statins to PCSK9 inhibitors
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower LDL-cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL-cholesterol lowering treatment. Data from over 25 cardiovascular outcome trials confirm tha...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American College of Cardiology
2020
|